NCT06387134View on ClinicalTrials.gov

Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

January 1, 2025

Study Completion Date

May 31, 2025

Conditions
Early Stage Lung Adenocarcinoma
Interventions
DRUG

Lifei Xiaoji Wan

The Lifei Xiaoji Wan consists of ginseng, blackhead,rhubarb, aster, forehu, and thin on.

DRUG

Conventional treatment with Western medicine

"Recommended treatment protocols for patients with Stage Ia NSCLC in the Chinese Society of Oncology Branch of Lung Cancer Clinical Diagnosis and Treatment Guidelines for Lung Cancer (2021 edition) and the Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Diagnosis and Treatment Guidelines 2021."

Trial Locations (1)

Unknown

RECRUITING

Mingli Zhao, Zhengzhou

All Listed Sponsors
lead

Henan University of Traditional Chinese Medicine

OTHER